Screener
Xeris Biopharma Holdings, Inc. XERS Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s accounts receivable?
- Xeris Biopharma Holdings, Inc. (XERS) reported accounts receivable of $58.11M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s accounts receivable changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s accounts receivable increased by 9.5% year-over-year, from $53.05M to $58.11M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s accounts receivable?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s accounts receivable has grown at a 53.9% compound annual growth rate (CAGR), from $36.44M to $204.18M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Xeris Biopharma Holdings, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude